ANASTASIOS GIANAKAKOS
CIK 1413822 · President & CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
123
Lifetime Open-Market Net
-$17.46M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | President & CEO | 548,513 | — | — | $0 | 1 | 2026-06-22 |
| LianBio (LIAN) Delisted | Director | 382,471 | $0.32 | $122.0K | $0 | 4 | 2024-02-20 |
| MyoKardia, Inc. (MYOK) Delisted | President and CEO | 72,209 | — | — | -$13.62M | 64 | 2020-07-07 |
| MAPP | SVP, Chief Business Officer | 0 | $27.50 | $0 | -$3.84M | 53 | 2013-03-04 |
Recent Filings · Page 3 of 13
123 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-01-07 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −12,687 | -$868.4K | EDGAR |
| 2020-01-03 | MyoKardia, Inc. (MYOK) Delisted | Mixed | +22,950 | -$359.0K | EDGAR |
| 2019-12-04 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −5,000 | -$325.1K | EDGAR |
| 2019-11-06 | MyoKardia, Inc. (MYOK) Delisted | Mixed | −4,956 | -$293.6K | EDGAR |
| 2019-10-04 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −5,000 | -$264.1K | EDGAR |
| 2019-09-12 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −1,000 | -$55.0K | EDGAR |
| 2019-09-05 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −4,000 | -$208.6K | EDGAR |
| 2019-08-09 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −1,000 | -$55.1K | EDGAR |
| 2019-08-05 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −4,000 | -$212.9K | EDGAR |
| 2019-07-23 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −1,000 | -$55.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.